AstraZeneca

News

AstraZeneca partners Capitainer on biomarker project

Swedish medtech start-up Capitainer has started working with AstraZeneca on a project to use a device for sampling cell-free blood in clinical trial programmes.

News

FDA pulls AZ's Evusheld for COVID, citing lack of efficacy

AstraZeneca's revenue boost from COVID-19 therapy Evusheld looks set to be curbed early, as the FDA withdraws authorisation for the antibody on the grounds that it is ineffective against mo

News

EU clears Enhertu for HER2-low breast cancer

The European Commission has approved Daiichi Sankyo and AstraZeneca's Enhertu as the first targeted therapy for HER2-low breast cancer, unlocking a large population of patients who could be

News

Merck's Keytruda flunks another prostate cancer test

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co's checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial.

News

BMS lawsuit claims AZ's Imjudo infringes Yervoy patents

AstraZeneca followed a long and arduous road to bring its CTLA4 inhibitor Imjudo to market, and will now have to defend its new product from a patent infringement complaint brought by Brist

Digital

Ovarian cancer, Olivia, and the OCC – part one

Following the European Society of Gynaecological Oncology (ESGO) 2022 congress, pharmaphorum spoke with experts from among the Ovarian Cancer Commitment (OCC) founding partners – ESGO, the

AstraZeneca partners Capitainer on biomarker project

FDA pulls AZ's Evusheld for COVID, citing lack of efficacy

EU clears Enhertu for HER2-low breast cancer

Merck's Keytruda flunks another prostate cancer test

BMS lawsuit claims AZ's Imjudo infringes Yervoy patents

Ovarian cancer, Olivia, and the OCC – part one

Nine more companies sign pricing deals with Trump

How to meet your physicians where they are online

AstraZeneca

Editor's Picks